New Therapeutics for Diabetes Using Incretin Hormone.
- Author:
Seungjoon OH
1
Author Information
1. Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
- Publication Type:Review ; Clinical Trial
- Keywords:
Incretin;
GLP-1;
DPP-4 inhibitors;
Diabetes
- MeSH:
Adamantane;
Dipeptidyl-Peptidase IV Inhibitors;
Glucagon-Like Peptide 1;
Hypoglycemia;
Incretins;
Insulin;
Nitriles;
Peptides;
Pyrazines;
Pyrrolidines;
Receptors, Glucagon;
Triazoles;
Venoms;
Glucagon-Like Peptide-1 Receptor;
Liraglutide;
Sitagliptin Phosphate
- From:Korean Journal of Medicine
2011;80(6):625-634
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
New therapeutics for type 2 diabetes using incretin hormone were introduced recently. Incretin-based therapies consist of two types: GLP-1 agonists mainly acting on the GLP-1 receptor and dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors). The former is resistant to DPP-4 and injectable. The latter is oral medications raising endogenous GLP-1 by inhibiting the degrading enzyme DPP-4. The incretin based therapies are promising and more commonly used due to their action and safety profile. Stimulation of insulin secretion by these drugs occurs in a glucose-dependent manner. Incretin based therapies have low risk for hypoglycemia. The subsequent review outlines evidence from selected clinical trials of the currently available GLP-1 agonists, exenatide and liraglutide, and DPP-4 inhibitors, sitagliptin and vildagliptin.
